Thomas Reuters

See the following -

Price Doesn't Always Buy Prestige In Open Access

Zoë Corbyn | Nature | January 22, 2013

The open-access journals that charge the most aren't necessarily the most influential, an online interactive tool suggests. The freely accessible tool, launched earlier this month, shows that a journal's fees do not correlate particularly strongly with its influence, as measured by a citation-based index. Read More »

Thomson Reuters Launches New Clinical Trial Intelligence Solution

Press Release | Thomas Reuters | October 18, 2013

Cortellis Clinical Trials Intelligence enables users to accelerate clinical trial development decisions and portfolio strategy Read More »